Among the infectious diseases in June, 19, hand, foot and mouth disease, cold and hepatitis took the first place

On August 2, the National Bureau of disease control and prevention publicized the national epidemic situation of legal infectious diseases in June 2019: a total of 964457 cases of legal infectious diseases were reported nationwide (excluding Hong Kong, Macao Special Administrative Region and Taiwan region, the same below), and 2118 people died Among them, there was no report of plague and death in class A infectious diseases, and no report of death in one case of cholera Among the class B infectious diseases, SARS, poliomyelitis, highly pathogenic avian influenza, diphtheria and h7n9 avian influenza were not reported 319934 cases and 2105 deaths were reported for the other 21 class B infectious diseases The top five diseases reported were viral hepatitis, tuberculosis, syphilis, dysentery and scarlet fever, accounting for 91% of the total cases of class B infectious diseases Filariasis was not reported in class C infectious diseases, and 644522 cases and 13 deaths were reported in other 10 class C infectious diseases The top three reported diseases were hand, foot and mouth disease, influenza and other infectious diarrhea, accounting for 92% of the total reported cases of class C infectious diseases From the data provided by the Chinese side in the above table, we can see that the top five of the three infectious diseases of a, B and C are hand foot and mouth disease, influenza, viral hepatitis, infectious diarrhea and tuberculosis The number of patients is basically 10W +, of which, two of the class b diseases are viral hepatitis and tuberculosis, respectively By comparing the incidence from 15 to June 19, we can see that the basic wave of the number of patients is roughly the same The increase of short-term drug use is not significant In 2019, the number of hepatitis B patients is 70% of the number of influenza patients, the largest proportion of the base number, and the same with tuberculosis For the manufacturers of hepatitis B drugs and tuberculosis drugs, their profits will not fluctuate too much for a long time This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.